Camrelizumab vs Nivolumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Camrelizumab
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
NCT03134872 · Phase 3 · completed
CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).
Next expected readout: December 2027 · NCT07016126 (registry estimate)
Reported efficacy
Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)
Result source: NCT03134872
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT01673867 · Phase 3 · completed
This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)
Result source: NCT01673867
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Camrelizumab | Nivolumab |
|---|---|---|
| PFS, median | 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872 | 12.1 vs 8.1+4 vs placeboNCT0311704922 other results
|
| OS, median | —Not posted · NCT03134872 | 12.2 vs 9.4vs DocetaxelNCT0167386720 other results
|
| ORR | 16.7%bNCT03083041 | 61.5% vs 50.5%+11 vs placeboNCT0311704919 other results
|
| Duration of response, median | —Not posted · NCT03134872 | 11 vs 7+4 vs placeboNCT0311704912 other results
|
PFS, median
- Camrelizumab
- 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
- Nivolumab
- 12.1 vs 8.1+4 vs placeboNCT03117049
22 other results
- 5.1 vs 5.5 NCT02477826
- 4.2 vs 5.5 NCT02477826
- 4.9 vs 5.5 NCT02477826
- 5.5 vs 5.5 NCT02477826
- 8.3 vs 5.5 NCT02477826
- 5.8 vs 5.5 NCT02477826
- 16.7 vs 15.6 NCT04026412
- 5.6 vs 5.5 NCT02864251
- 1.5 vs 5.5 NCT02864251
- 4.2 vs 5.9 NCT02041533
- 2.3 vs 4.4 NCT01673867
- 3.5 vs 2.8 NCT01642004
- 16.8 vs 15.7 NCT04026412
- 17.4 vs 15.7 NCT04026412
- 16.8 vs 16.5 NCT04026412
- 17.7 vs 16.5 NCT04026412
- 4.2 vs 5.8 NCT02041533
- 3.7 NCT03090737
- 5.2 NCT02659059
- 10.8 NCT02659059
- 2 NCT05061017
- 2 NCT05061017
OS, median
- Camrelizumab
- —Not posted · NCT03134872
- Nivolumab
- 12.2 vs 9.4vs DocetaxelNCT01673867
20 other results
- 9.2 vs 6.0 NCT01642004
- 17.1 vs 14.9 NCT02477826
- 15.7 vs 14.9 NCT02477826
- 17.4 vs 14.9 NCT02477826
- 15.2 vs 14.9 NCT02477826
- 18.3 vs 14.9 NCT02477826
- 21.0 vs 14.9 NCT02477826
- 12.0 vs 9.6 NCT02613507
- 25.4 vs 24.7 NCT03117049
- 12.2 vs 9.5 NCT01673867
- 9.2 vs 6.0 NCT01642004
- 34.6 vs 39.8 NCT04026412
- 39.5 vs 39.8 NCT04026412
- 19.4 vs 15.9 NCT02864251
- 17.1 vs 15.9 NCT02864251
- 14.4 vs 13.2 NCT02041533
- 13.7 vs 13.8 NCT02041533
- 10.6 NCT03090737
- 20.8 NCT02659059
- 19.4 NCT02659059
ORR
- Camrelizumab
- 16.7%bNCT03083041
- Nivolumab
- 61.5% vs 50.5%+11 vs placeboNCT03117049
19 other results
- 19.5% vs 12.8% NCT01673867
- 20% vs 8.8% NCT01642004
- 36.4% vs 29.7% NCT02477826
- 27.5% vs 29.7% NCT02477826
- 26.2% vs 29.7% NCT02477826
- 37.9% vs 29.7% NCT02477826
- 52.3% vs 29.7% NCT02477826
- 38.1% vs 29.7% NCT02477826
- 67.6% vs 64.5% NCT04026412
- 72.2% vs 64.5% NCT04026412
- 61.3% vs 57.9% NCT04026412
- 63.1% vs 57.9% NCT04026412
- 26.1% vs 33.5% NCT02041533
- 50.6% vs 43% NCT04623775
- 14.5% NCT01721759
- 17.1% NCT03090737
- 15.4% NCT01721759
- 32.3% NCT02659059
- 47.2% NCT02659059
Duration of response, median
- Camrelizumab
- —Not posted · NCT03134872
- Nivolumab
- 11 vs 7+4 vs placeboNCT03117049
12 other results
- 25.8 vs 25.2 NCT04026412
- 31.8 vs 25.2 NCT04026412
- 22.8 vs 27.9 NCT04026412
- 33.2 vs 27.9 NCT04026412
- 17.1 vs 5.5 NCT01673867
- 24.5 vs 8.4 NCT01642004
- 6.7 vs 5.5 NCT02864251
- 50.0 vs 5.5 NCT02864251
- 12 NCT01721759
- 8.4 vs 7.1 NCT04623775
- 35.5 NCT03090737
- 16 NCT01721759
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Camrelizumab: 4 of 5 rows · Nivolumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camrelizumab Rows use multiple source trials | Nivolumab Rows use multiple source trials |
|---|---|---|
| ORR responder rate · % of participants No placebo or comparator arm | 16.7% (n=12)375 mga,b,c NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 17.1% (n=129)480mg Q4Wa,b,c NCT03090737 · Phase 2 · registry result, not featured evidence 4 other source trials32.3% (n=288) NCT02659059 · Phase 2 · registry result, not featured evidence · combination 47.2% (n=36) NCT02659059 · Phase 2 · registry result, not featured evidence · combination 14.5% (n=117)3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence 15.4% (n=117)3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 91.7%375 mgd NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | —480 mge NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%360 mg NCT02998528 · Phase 3 · combination 0.9%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 1.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 1.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 1.1%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 2.8%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.5%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 66% NCT03444766 · Phase 4 · registry result, not featured evidence 64.1%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 73.1% NCT03117049 · Phase 3 · registry result, not featured evidence 0.3% NCT02613507 · Phase 3 · registry result, not featured evidence 2.1%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 2.7%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT02041533 · Phase 3 · registry result, not featured evidence 1.1%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 1.6%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy n/a: no completion milestoneNivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 88.2%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 90.6%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 2.5%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 8.7%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 23.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 0%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 37.9% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 87.2%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 88.9%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —375 mgd NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | —480 mge NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.3%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.7%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.6%360 mg NCT02998528 · Phase 3 · combination 0%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 0.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 0%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 0.5%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 0%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.3%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 6% NCT03444766 · Phase 4 · registry result, not featured evidence —Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination —Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination — NCT03117049 · Phase 3 · registry result, not featured evidence — NCT02613507 · Phase 3 · registry result, not featured evidence 0.7%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 0%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination — NCT02041533 · Phase 3 · registry result, not featured evidence —480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 3.8%Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 11.8%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 5%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence —Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination —Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 4.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 13.8% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 5.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 11.1%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 11.1%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 9.4%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 58.3%375 mgd NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result56.6%250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 33.3%480 mge NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results59.9%3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 16.7%480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 64.9%3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 30.1%360 mg NCT02998528 · Phase 3 · combination 27%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 61.1%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 70.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 69.2%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 65.1%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 64%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 61.9%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 30% NCT03444766 · Phase 4 · registry result, not featured evidence 63.8%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.4% NCT03117049 · Phase 3 · registry result, not featured evidence 54.3% NCT02613507 · Phase 3 · registry result, not featured evidence 54.6%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 64.8%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 73% NCT02041533 · Phase 3 · registry result, not featured evidence 34.8%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 39.4%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 44.9%Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 41.6%Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 60.9%Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 70.6%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 41%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 59.7%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 65.2%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 17.4%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 14.3%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 31.8%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 13.6%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination 37.5%Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 20%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 100%600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 43.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 59.4%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 72.2%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 75.2%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 375 mgd rash 91.7% hypertension 83.3% decreased appetite 75% NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result250 mg hypertension 63.6% proteinuria 63.1% aspartate aminotransferase increased 53.5% NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 480 mge cough 33.3% arthralgia 20% rash 20% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 40 more results3 mg/kg fatigue 33.4% decreased appetite 31.7% cough 28.9% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 480 mg nausea 33.3% vomiting 33.3% abdominal pain 16.7% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3 mg/kg dyspnoea 35.9% cough 34.4% fatigue 32.1% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 50% hyponatraemia 37.3% aspartate aminotransferase increased 36.5% NCT02477826 · Phase 3 · combination anaemia 44% nausea 34.8% constipation 29.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination anaemia 41.5% nausea 32.7% cough 26.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination constipation 54.9% (placebo 48.7%) alopecia 52.4% (placebo 54.5%) peripheral sensory neuropathy 44.3% (placebo 42.2%) NCT03117049 · Phase 3 · registry result, not featured evidence anaemia 34.7% decreased appetite 31.5% fatigue 31.2% NCT02613507 · Phase 3 · registry result, not featured evidence anaemia 46.8% nausea 44.7% constipation 36.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination constipation 29.6% pruritus 25.4% diarrhoea 23.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination fatigue 40.4% decreased appetite 34.1% nausea 32.2% NCT02041533 · Phase 3 · registry result, not featured evidence 480 mg every 4 weeks diarrhoea 16.9% pruritus 16.9% fatigue 15.7% NCT02713867 · Phase 3 · registry result, not featured evidence 240 mg every 2 weeks pruritus 23.3% diarrhoea 22.8% fatigue 22.2% NCT02713867 · Phase 3 · registry result, not featured evidence diarrhoea 28.3% arthralgia 23.6% upper respiratory tract infection 22% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy cough 17.6% weight decreased 16% arthralgia 14.4% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy fatigue 36.1% dyspnoea 23.7% nausea 23.2% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy anaemia 41.2% cough 41.2% hyponatraemia 35.3% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 40.5% decreased appetite 24.5% cough 22.2% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 66.2% fatigue 42.9% nausea 42.9% NCT04623775 · Phase 2 · registry result, not featured evidence · combination anaemia 69% nausea 34.8% thrombocytopenia 29.7% NCT04623775 · Phase 2 · registry result, not featured evidence · combination fatigue 34.8% anemia 30.4% rash acneiform 26.1% NCT03158129 · Phase 2 · registry result, not featured evidence rash acneiform 61.9% cough 38.1% fatigue 38.1% NCT03158129 · Phase 2 · registry result, not featured evidence · combination nausea 81.8% fatigue 72.7% anemia 54.5% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 50% diarrhea 40.9% nausea 40.9% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 62.5% fatigue 50% hyponatremia 50% NCT05061017 · Phase 2 · registry result, not featured evidence · combination activated partial thromboplastin time prolonged 80% hypertriglyceridemia 60% hyponatremia 60% NCT05061017 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 100% hypoalbuminemia 93.1% anemia 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 600 mg blood alkaline phosphatase increased 100% blood lactate dehydrogenase increased 100% bronchitis 100% NCT05005273 · Phase 2 · registry result, not featured evidence · combination 480mg Q4W anaemia 28.7% blood alkaline phosphatase increased 24.8% rash 20.2% NCT03090737 · Phase 2 · registry result, not featured evidence fatigue 55.2% diarrhoea 38.5% nausea 38.2% NCT02659059 · Phase 2 · registry result, not featured evidence · combination fatigue 55.6% pruritus 47.2% nausea 44.4% NCT02659059 · Phase 2 · registry result, not featured evidence · combination 3 mg/kg fatigue 53% decreased appetite 39.3% dyspnoea 38.5% NCT01721759 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
- ePopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 18 more results
show 14 more results
show 5 more results
show 9 more results
show 2 more results
show 11 more results
show 8 more results
show 1 more result
show 2 more results
show 5 more results
+ 39 further endpoints in the CSV export.
Hepatocellular Carcinoma
Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline
Camrelizumab
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05062837 (registry estimate)
No aligned efficacy figure on record for this race.
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT04039607 · Phase 3 · completed
This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.
Next expected readout: December 2026 · NCT07176650 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hepatocellular Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Camrelizumab: registry results are on file for Hepatocellular Carcinoma, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
show 1 more result
show 1 more result
Available safety results
Nivolumab
| Dropout rate | 0%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results20%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | 0%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results0%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 33.3%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results40%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 50%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 52%Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | vomiting 66.7% dehydration 33.3% depression 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more resultsdiarrhoea 40% pulmonary embolism 40% abdominal pain 20% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 33.3% headache 33.3% hyperglycaemia 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination amylase increased 75% aspartate aminotransferase increased 50% blood alkaline phosphatase increased 50% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination gingivitis 100% rhinorrhoea 100% abdominal distension 0% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination pruritus 36% decreased appetite 28% diarrhoea 28% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
Gastric Cancer
Shared mechanism: PD-1 · full Gastric Cancer pipeline
Camrelizumab
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04208347 (registry estimate)
No aligned efficacy figure on record for this race.
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02872116 · Phase 3 · completed
The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.
Next expected readout: December 2026 · NCT04900818 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Gastric Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Camrelizumab: no structured comparison results are available for Gastric Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
Available safety results
Nivolumab
| Dropout rate | 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results—0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Nivolumab's landscape